Can addressing immune dysfunction help close the treatment durability gap in HR-MDS and AML?

Can addressing immune dysfunction help close the treatment durability gap in HR-MDS and AML?

Can addressing immune dysfunction help close the treatment durability gap in HR-MDS and AML?

Can addressing immune dysfunction help close the treatment durability gap in HR-MDS and AML?

Watch Dr Komrokji discuss present and possible future treatments for HR-MDS and AML

 
  • Current treatment options offer limited durability and short median durations of response1,2
  • With few treatment advances, patients with HR-MDS remain at risk for transformation to AML3
  • “An immunotherapeutic approach for myeloid diseases, or immuno-myeloid therapy, may be a promising way to address immune dysfunction”
    —Rami Komrokji, MD
 
  Scroll for more
Rami Komrokji, MD, Vice Chair,
Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

 

“An immunotherapeutic approach for myeloid diseases, or immuno-myeloid therapy, may be a promising way to address immune dysfunction”
—Rami Komrokji, MD

  • An immuno-myeloid approach harnesses the immune system to eliminate malignant myeloid cells in patients with HR-MDS and AML
LEARN MORE ABOUT HOW TIM-3 MAY BE A KEY PLAYER IN HR-MDS AND AML

 

Current treatments offer limited durability and short median durations of response1,2

  • Median duration of response is ~13 months with HMAs in patients with HR-MDS and 17.5 months with an HMA/BCL-2 combination in patients with AML1,2
  • OS is as low as 9.6 months in patients with HR-MDS with a very high-risk IPSS-R score and is <12 months in patients with AML3-5
  • Longer durations of HMA treatment have shown better outcomes, but only 37% of patients remain on therapy for <12 courses6
CAN FOCUSING ON TIM-3 EXPRESSION ADDRESS IMMUNE DYSFUNCTION?

 

With few treatment advances, patients with HR-MDS remain at risk for transformation to AML3

1 in 4 patients will develop AML after a median duration of 8.8 to 16.7 months
1 in 4 patients will develop AML after a median duration of 8.8 to 16.7 months
 
  • 1 in 4 patients will develop AML after a median duration of 8.8 to 16.7 months3
CAN ADDRESSING TIM-3 EXPRESSION BRING ABOUT NEW ADVANCEMENTS IN TREATMENT?

 

 

Learn more about the treatment durability gap by hearing Dr Wei discuss the limitations of current treatments for HR-MDS and AML

 
Andrew Wei, MBBS, PhD, Cancer Agency Research Fellow and Hematologist,
Alfred Hospital at Monash University, Australia
 

AML, acute myelogenous leukemia; BCL-2, B-cell lymphoma 2; DC, dendritic cell; HMA, hypomethylating agent; HR-MDS, higher-risk myelodysplastic syndromes; IPSS, International Prognostic Scoring System; NK, natural killer; OS, overall survival; PFS, progression-free survival; TIM-3, T cell immunoglobulin and mucin domain-3.

 
References: 1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232. 2. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. New Engl J Med. 2020;383(7):617-629. 3. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465 4. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670-2677. 5. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291-299. 6. Cabrero M, Jabbour E, Ravandi F, et al. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. Leuk Res. 201;39(5):520-524.